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ABSTRACT
Cholera toxin (CT) enters the cell via receptor-mediated endocytosis and travels
in a retrograde fashion to the endoplasmic reticulum (ER). The catalytic A1 subunit
(CTA1) is then displaced from the rest of the holotoxin, unfolds, and is exported to
the cytosol where it regains an active conformation for the ADP-ribosylation of its
G-protein target. We have shown that the cytosolic chaperones Hsp90 and Hsc70
are required for CTA1 translocation to the cytosol. We have also shown that both
are able to independently bind and refold CTA1. Using libraries of CTA1-derived
peptides, we have identified a single Hsc70 binding site, YYIYVI (CTA183-88), within
the 192 amino acid protein, as well as two distinct Hsp90 binding sites: an Nterminal RPPDEI (CTA111-16) motif and a C-terminal LDIAPA (CTA1153-158) motif.
The LDIAPA motif is unique to CTA1, but an RPPDEI-like motif is present in four
other ER-translocating ADP-ribosylating toxins: pertussis toxin, Pseudomonas
aeruginosa exotoxin A, Escherichia coli heat-labile toxin, and Salmonella
typhimurium ADP-ribosylating toxin. Using site-directed mutagenesis to further
investigate the RPPDEI motif, we found that a modification of either proline residue
blocks CTA1 translocation to the cytosol. Our work has identified, for the first time,
specific amino acid sequences that are recognized by Hsp90/Hsc70 and are
essential for toxin translocation from the ER to the cytosol. CT does not require
prolyl isomerases for cellular activity, as is the case for Hsp90-dependent
endosome-translocating toxins. We therefore hypothesize that the one or both of
the prolines within the RPPDEI motif of CTA1 undergo an isomerization event as
iii

CTA1 unfolds in the ER. Furthermore, we predict that the trans- to cisconformational change of proline(s) is the molecular determinate for the atypical
Hsp90 interaction observed with CTA1 and related toxins. Additionally, we have
identified Hsp90 and other host factors required for the translocation of pertussis
toxin.
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CHAPTER 1 INTRODUCTION
Upon entering the endoplasmic reticulum (ER), the folding of a newly synthesized
protein is orchestrated by ER chaperones. Chaperones of the ER can be divided
into classical chaperones, carbohydrate-binding chaperones, oxidoreductases,
and proline isomerases [1]. Unique complexes of chaperones interact with different
proteins at different times while in the ER. While it is clear that none of these
chaperones work alone, it is still unclear what determines which clients interact
with which complexes of chaperones, and at what time. The classical chaperone
family is found throughout the entire cell and is dedicated to the proper folding of
proteins [1, 2]. It consists of chaperones from the Hsp90 family as well as the
Hsp70 family. The carbohydrate-binding chaperones of the ER, calnexin and
calreticulin, recognize misfolded proteins and initiate the refolding process [3-5].
Oxidoreductases catalyze proper disulfide bond formation and reduction during
protein folding [6, 7]. Proline isomerases catalyze cis/trans isoforms of proline
bonds, which is thought to be the rate-limiting step of the entire protein folding
process [8].

Endoplasmic Reticulum-Associated Degradation
Protein folding is an error-prone process that can result in incorrectly folded protein
aggregates. ER chaperone complexes work to refold these misfolded proteins to
their correct conformations, although that is not always possible. Terminally
misfolded proteins are disposed of by endoplasmic reticulum-associated
1

degradation (ERAD), a quality control mechanism [2, 8]. There are 4 phases of
ERAD: client recognition by chaperone complexes, retrotranslocation to the
cytosol, membrane unload, and degradation [2, 9]. ER chaperone client
recognition is dictated by co-chaperones and different substrates require different
complexes of chaperones for their disposal through ERAD [9-11].

AB toxins that exploit ERAD
A group of AB toxins (Figure 1) have evolved to hijack ERAD for their productive
intoxication. These AB toxins share a common structure consisting of a catalytic A
subunit and a cell-binding B pentamer [12]. Upon internalization, the toxin travels
through the Golgi and eventually to the ER where the A subunit dissociates from
the rest of the toxin before it is exported to the cytosol. ERAD substrates are
typically ubiquitinated for their subsequent degradation in the cytosol, but toxin A
chains are have evolved to escape degradation. Instead they are refolded in the
cytosol, presumably by host factors, and go on to modify their cytosolic target [13].
These toxins include cholera toxin (CT), Escherichia coli heat-labile toxin (LT),
pertussis toxin (PT), Salmonella enterica serovar Typhimurium ADP-ribosylating
toxin (ArtAB), Pseudomonas aeruginosa exotoxin A (ETA), Shiga toxin (ST), and
ricin (RT). Even though they are all AB toxins they do not all have the same
catalytic activity.
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Figure 1 Structure of AB toxins that exploit ERAD
Cholera toxin (CT, PDB 1XTC), Escherichia coli heat-labile toxin (LT, PDB 1LTA),
pertussis toxin (PT, PDB 1PRT), Pseudomonas exotoxin A (ETA, PDB 1IKQ),
Shiga toxin (ST, PDB 1R4Q) and ricin (RT, PDB 2AAI) belong to a subset of
bacterial AB toxins that exploit ERAD. AB toxins have a catalytic A subunit (cyan)
and a cell-binding B subunit (pink). The A2 linkers of CT, LT, and ST are shown in
purple.

3

Cholera and heat-labile toxins
CT is made by Vibrio cholerae and causes a diarrheal illness termed cholera [14].
It is an AB5 toxin that has a catalytic A1 subunit disulfide linked to an A2 linker that
is non-covalently anchored within the B pentamer. The B pentamer recognizes
GM1 ganglioside receptors on the host cell [15]. Once inside the cytosol, CT uses
NAD as a donor molecule to ADP-ribosylate its Gs protein target. The modification
locks Gs, an adenylate cyclase activator (AC), into an “ON” state so AC is
constantly stimulated to produce 3’,5’-cyclic AMP (cAMP) [13, 14]. Protein kinase
A (PKA) is activated by the increased levels of cAMP within the cell and goes on
to phosphorylate CFTR chloride channel proteins. Chloride ions are shuttled out
of the cell into the intestinal lumen which results in water leaving the cell ultimately
causing the watery stool associated with cholera [15].

The structure of LT closely resembles that of CT, which can be attributed to ~80%
homology shared between the two toxins [16, 17]. LT, like CT, travels to the ER
where the holotoxin is then disassembled. LTA1 is exported to the cytosol where
it is refolded, presumably by the same host factors that refold CTA1. LTA1 also
modifies Gs which results in increased levels of cAMP within the cell. As is the
case with CT, the increased cAMP levels ultimately result in Cl- ions, followed by
water, leaving the cell which causes the diarrheal illness typically associated with
LT [18, 19].
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Shiga toxin
ST is made by Shigella dysenteriae whereas, Shiga-like toxins are made by Shiga
toxin-producing Escherichia coli (STEC). Shiga toxins share the same AB5 toxin
structure as CT and LT, although their catalytic activities are different. The B
pentamer associates with Gb3, allowing the toxin to be internalized. Using
retrograde transport, the toxin travels to the ER. The A subunit dissociates from
the rest of the toxin and is subsequently exported to the cytosol where it acts as a
potent protein synthesis inhibitor by inhibiting the ribosome [9, 20-22]. Depurination
of an adenine residue within the 28S RNA by ST results in a loss of interaction with
EF-2. Without the GTPase activity of EF-2, required for the translocation step of
protein synthesis, the ribosome stalls and synthesis is halted [23].

Pertussis toxin
PT is AB5 toxin produced by Bordetella pertussis and is the causative agent of
whooping cough. Its B pentamer is made up of an S5 subunit that links together
two dimers (S2/S4 and S3/S4) and has many receptors, mostly glycoconjugated
molecules. The enzymatic A subunit is called S1 and has ADP-ribosyltransferase
activity, but it modifies different G proteins (Gi/o) than CT and LT [24, 25].
Modification of Gi renders it inactive resulting in a constant stimulus of AC. The
resulting increases in cAMP within the cell causes a signaling dysfunction within
the cell [26, 27].

5

Exotoxin A
Pseudomonas aeruginosa makes an ADP-ribosylating toxin (ADPRT) called
exotoxin A (ETA) [28]. It is an AB toxin consisting of a single protein that has a
catalytic domain and a cell binding domain. ETA utilizes NAD as a donor for the
ADP-ribosylation of EF-2, which is required for elongation. Protein synthesis is
arrested, ultimately leading to death of the cell [29-33].

Ricin
Ricin, another AB toxin derived from a single protein, is an extremely potent plant
toxin that comes from the seeds of Ricinus communis. This toxin inhibits protein
synthesis by exhibiting N-glycosylase activity against an adenine residue within
the 28S rRNA. Cell death ultimately results from the loss of protein synthesis [23,
34-38].

Hsp90 is required for CTA1 translocation
ERAD substrates typically require p97 for their extraction from the ER but a subset
of AB toxins exploit cytosolic chaperone Hsp90 for this purpose [39-41]. The
extraction of CTA1 requires the actions of Hsc70, in addition to Hsp90, and occurs
via a ratchet mechanism [42, 43]. Refolding is coupled to translocation, ensuring
a unidirectional export of CTA1. Folding by Hsp90 occurs in an ATP-dependent
fashion and ensures the toxin cannot slide backwards through the translocon pore.

6

Hsp90 remains associated with folded CTA1 to maintain it in an active
conformation for the modification of Gs.

Hsp90 has a wide range of client proteins and exhibits a higher client specifity than
other chaperones [44]. Hsp90 client recognition is dictated by co-chaperones,
however, CTA1 can interact with Hsp90, in addition to Hsc70, independent of cochaperones [42, 43, 45]. This suggests that the interactions between CTA1 and
cytosolic chaperones Hsp90 and Hsc70 are extremely atypical. It is likely that
Hsp90 and Hsc70 recognize distinct sites within CTA1 as they are able to interact
with CTA1 simultaneously and independent of each other. Furthermore, Hsp90 is
only able to recognize disordered CTA1 while Hsc70 recognizes both the folded
and unfolded forms [42]. A binding motif has not yet been identified for Hsp90 or
Hsc70 within CTA1, or any other client protein.

We have identified a YYIYVI binding motif within CTA1 that was specifically
recognized by Hsc70. We also demonstrated that Hsp90 recognizes two distinct
binding sites within CTA1, RPPDEI and LDIAPA. The first three amino acids of the
RPPDEI motif are conserved in other toxin A chains that utilize Hsp90 for their
productive intoxication. A mutation to any of the RPP residues within CTA1 blocks
the export of CTA1 to the cytosol, suggesting all three are required for the
interaction with Hsp90. Additionally, we have shown that Hsp90, and others, are
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required for the translocation of PTS1 to the cytosol. Furthermore, we predict that
proline isomerization is a key determinate of the Hsp90-toxin interaction.
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CHAPTER 2: METHODS
CTA1 expression and purification
Escherichia coli strain BL21(DE3)pLysS containing expression plasmid CTA1Hisx6/pET-22(b) was grown overnight at 37°C in Luria broth (LB) supplemented
with 100 μg/mL of ampicillin. The culture was used to inoculate a larger volume of
LB supplemented with ampicillin and was incubated at 37°C until an O.D.600 of 0.60.8 was achieved. A final concentration of 1 mM IPTG was used to induce protein
expression for 18 h at 25°C. The culture was centrifuged (6,000 x g for 30 min at
4°C), and the resulting cell pellet was resuspended in lysis buffer (20 mM Tris-HCl
pH 7.0, 300 mM NaCl, 8 M urea, 0.1% Triton-X-100, 1% sodium deoxycholate,
100 μg/mL lysozyme). Lysis was allowed to proceed at 37°C for 20-30 minutes
before the lysate was sonicated for 3 minutes. The lysate was subjected to a
second centrifugation step (16,000 x g for 30 min at 4°C), and the resulting
supernatant was transferred to equilibrated TALON (Takara Bio, Mountain View,
CA) resin. The resin and lysate were incubated together overnight at 4°C in the
presence of 1X EDTA-free protease inhibitor (Pierce Biotechnology, Rockford, IL).
The TALON resin was then washed 3 times with wash buffer (20 mM Tris-HCl pH
7.0, 600 mM NaCl, 8 M urea, 0.1% Triton-X100) before it was loaded into a gravity
column. After an additional wash with extraction buffer (20 mM Tris-HCl pH 7.0,
600 mM NaCl, 8 M urea), CTA1 was eluted from the column using an imidazole
gradient (10, 15, 20, 25, 35, 40 and 50 mM). Fractions were then separated by
SDS-PAGE (15% acrylamide) and analyzed for purity by Coomassie staining.
9

Fractions containing pure protein, as indicated by a single strong band on the gel,
were pooled and refolded by step-wise dialysis against 20 mM sodium phosphate
buffer (pH 7.0) containing 150 mM NaCl. Final protein concentration was assessed
using a commercially-available BCA kit (Pierce Biotechnology). Dialyzed CTA1
samples were then frozen at -80°C overnight to be lyophilized the following day.
Lyophilized CTA1 samples were stored at -80°C until use.

Surface plasmon resonance (SPR)
All SPR experiments were performed at 37°C using a Reichert (Depew, NY)
SR7000 SPR instrument with a flow rate of 41 μL/min. Full-length CTA1 or peptide
(Peptide 2.0, Chantilly, VA) was amide-coupled to an SPR sensor slide with a
mixed-assembled monolayer. First, the slide was washed with phosphate-buffered
saline with 0.1% Tween 20 (PBS-T, Medicago AB, Uppsala, Sweden). Next, the
slide was activated for 300 seconds with 0.02 mg/ml NHS and 0.08 mg/ml EDC. 5
g of CTA1 or peptide was then diluted into sodium acetate buffer (pH 5.5) and
perfused over the activated slide for 300 seconds. To block the slide 1 M
ethanolamine was perfused over the CTA1-coated slide for 300 seconds. The slide
was then washed with PBS-T until a stable baseline signal was achieved. Hsp90
(1600 ng) with 1 mM ATP was added to the perfusion buffer for 180 seconds. After
the removal of Hsp90/ATP, the slide was washed with PBS-T for an additional 180
seconds. Hsp90 without ATP was used as a negative control for all experiments.
For competition assays, Hsp90/ATP was first incubated with an excess of the
10

indicated peptide for 10 minutes at room temperature before addition to the
perfusion buffer. SPR traces were processed using Reichert software, BioLogic
(Campbell, Australia) Scrubber2 software, and WaveMetrics (Lake Oswego, OR)
Igor Pro software.

Citrate Synthase assay
Citrate synthase (6 nM) was thermally denatured at 45°C for 90 minutes in the
presence of Hsc70, alone or with either a 4 or 8 molar excess of the indicated
peptide. Citrate synthase was denatured in the absence of chaperone to control
for thermal deactivation. After heating, 45 nM Acetyl-coA, 500 nM oxaloacetate,
and 100 nM DTNB were added to the samples. Reduced coenzyme-A is produced
from citrate synthase activity on Acetyl-coA and oxaloacetate; its reaction with
DTNB generates a colorimetric change that can be detected at 412 nm [46]. Citrate
synthase activity was monitored for 15 minutes at 30°C. Background-subtracted
experimental values are expressed as percentages of the maximal citrate synthase
activity when denatured in the presence of Hsc70 alone. Student’s t test was
performed using GraphPad Prism version 6.00 for Mac OS X (GraphPad Software,
La Jolla, CA).

Round-the-horn mutagenesis
The mammalian expression plasmid ssCTA1/ pcDNA3.1 (ssCTA1), which
encodes a CTA1 subunit that is co-translationally inserted into the ER via an N11

terminal signal sequence [47], was used as a template for site-directed
mutagenesis. Primers (10 M) containing the desired CTA1 mutation (Table 1)
were phosphorylated with 25 U T4 polynucleotide kinase (Thermo Fisher Scientific,
Waltham, MA) in 1X PNK Reaction Buffer A containing 1 mM ATP for 20 minutes
at 37C. The reactions were then halted by heating the samples to 75C for 10
minutes. Phosphorylated primers were then used to PCR amplify the entire
ssCTA1 plasmid. 10 ng template plasmid was mixed with 0.5 M of each
phosphorylated primer, and 1X Phusion HF master mix in a 0.2 l PCR tube.
Reactions were PCR amplified according to Table 2. The resulting linear mutant
ssCTA1/pcDNA3.1 plasmids were ligated overnight at 37C using T4 DNA ligase
(1X T4 Ligase buffer, 8 l PCR product, 5 U T4 ligase). To remove the wild-type
ssCTA1 template, 1 l FastDigest DpnI (Thermo Fisher Scientific, Waltham, MA)
was added to the ligation reaction. Ligated plasmids were transformed into
chemically-competent DH5α cells. Mutations were confirmed by DNA sequencing
(Genewiz, South Plainfield, NJ).
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Table 1 Site-directed mutagenesis primers (5'-3')
Construct Primer
TPPDEI
Forward
Reverse
RVPDEI
Forward
Reverse
RPVDEI
Forward
Reverse
CTA117-192
Forward
Reverse
CTA11-133
Forward
Reverse
CTA11-169
Forward
Reverse

Sequence
ACACCTCCTGATGAAATAAAGCAGTCAG
AGAATCTGCCCGATATAACTTATCATCATT
GTCCCTGATGAAATAAAGCAGTCAGGTG
TCTAGAATCTGCCCGATATAACTTATCATCATT
GTCGATGAAATAAAGCAGTCAGGTGG
AGGTCTAGAATCTGCCCGATATAACTTATCATC
AAGCAGTCAGGTGGTCTTATGCC
TGCATATGAAAATGATGATAAGAAAATAAAAAACACAAATATTATCTTTAC
TTAGCTGCAGGTCGACTCTAGAGG
CCAAAATGAACTCGATACC
TAGCTGCAGGTCGACTCTAGAGG
ACCATCTGCTGCTGGAGCAATATC

13

Table 2 PCR cycling conditions
Step
Initial denaturation

Temperature
98°

Time
30s

# of cycles
1

Denaturation
Annealing
Extension

98°
X
72°

5s
30s
15s/kb

35

Final extension

72°

7 min

1

X: the lowest Tm in each primer set +3C.
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Targeted translocation assay
CHO cells were seeded to 60-70% confluency in 6-well plates in Ham’s F-12 media
supplemented with 10% fetal bovine serum and antibiotic-antimycotic. All cell
culture reagents were from Gibco (Gaithersburg, MD), and all incubations were at
37°C with 5% CO2. Cells were first washed once with PBS and then transfected
with 1 μg/well of the indicated DNA using Lipofectamine (10 L/g DNA) as the
transfection reagent. The ssPtxS1/ pCMV/myc/ER expression vector [48] was
generously provided by Dr. Nicholas Carbonetti (Department of Microbiology and
Immunology, University of Maryland School of Medicine). After 3 hours, the
transfection mix was removed and replaced with Ham’s F-12 media supplemented
with 10% fetal bovine serum and incubated at 37°C. At 24 hours post-transfection,
cells were lifted using PBS supplemented with 0.5 mM EDTA. The contents of 3
wells for each condition were pooled together. Samples were then centrifuged at
5,200 x g for 2 min at 4°C, and the resulting pellets were chilled on ice for 10 min.
The pellets were then resuspended in HCN buffer (50 mM HEPES pH 7.5, 150
mM NaCl, 2 mM CaCl2, 10 mM N-ethylmaleimide, protease inhibitor cocktail)
containing 0.04% digitonin and incubated on ice for an additional 10 min. Cellular
components were then separated by centrifugation (14,000 x g for 10 min at 4°C).
Cytosolic fractions (i.e., supernatants) were collected and transferred to new tubes
for lyophilization. Both pellet (i.e., intact membranes) and supernatant samples
were resuspended in 2x sample buffer and separated by SDS-PAGE with 15%
polyacrylamide gels. Gels were transferred to PVDF membranes and blocked with
15

4% milk in Tris-buffered saline with 0.05% Tween 20 (TBS-T). The membranes
were incubated overnight at 4°C with either rabbit anti-CT antibody at 1:20,000
dilution (Sigma-Aldrich, St. Louis, MO) or rabbit anti-PT antibody at 1:30,000
dilution (Abcam, Cambridge, United Kingdom). Membranes were then washed 3
times with TBS-T and incubated for 1 hour at room temperature with an HRPconjugated goat anti-rabbit IgG antibody at 1:20,000 dilution (Jackson
ImmunoResearch, West Grove, PA). Following 3 additional washes with TBS-T,
the blots were developed using ECL solution (100 mM Tris pH 8.5, 0.2 mM coumaric acid, 1.25 mM luminol, and 0.01% H2O2).
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CHAPTER 3 AN HSC70 BINDING MOTIF IN THE CHOLERA
TOXIN A1 SUBUNIT
Introduction
When CT enters the cell (Figure 2), it travels in a retrograde fashion to the ER [49].
Once inside the ER, the catalytically-active A1 subunit (CTA1) dissociates from the
rest of the holotoxin and unfolds [50-52]. It is then exported to the cytosol by the
ERAD system [53-56]. Once in the cytosol, CTA1 relies on host factors to regain
an active conformation for the modification of its G protein target [42, 49]. Cytosolic
chaperones Hsp90 and Hsc70 provide the driving force for CTA1 extraction from
the ER using a ratchet mechanism that couples translocation with refolding [42,
43]. The refolding event ensures the unidirectional movement of the toxin A chain
as a folded toxin could no longer slides backwards through the translocon pore.
CTA1 remains chaperone associated which maintains it in an active conformation
for the ADP-ribosylation of Gs.

Hsp90-mediated refolding of client proteins often occurs in complex with Hsc70,
Hop, and Hsp40 [45, 57, 58]. Clients are initially recognized by Hsp40 before they
are transferred to Hsc70. The Hsc70/Hsp90-organizing protein (Hop) is then
recruited to the complex followed by Hsp90 [59-63]. Hop serves as a linker that is
required for the recruitment of Hsp90 to the Hsc70/client complex [64, 65]. We
have previously shown that CTA1 intoxication relies on both Hsp90 and Hsc70,
but not Hop, suggesting an atypical chaperone interaction with CTA1. Additionally,
17

Hsp90 only recognizes the disordered form of CTA1 while Hsc70 is able to
recognize both ordered and disordered states [42, 43]. This suggests that Hsp90
and Hsc70 most likely recognize distinct sites within the CTA1 polypeptide.

We used a CTA1-derived peptide library to identify a single Hsc70 binding site
within CTA1. Our results indicate that Hsc70 specifically recognizes a YYIYVI motif
within CTA1 spanning residues 83-88. Additionally, we have identified specific
amino acid substitutions within the YYIYVI motif of CTA1 that influence recognition
by Hsc70. Furthermore, we predict that CTA1 is most likely recognized within the
normal client recognition site of Hsc70, as the presence of a YYIYVI-containing
peptide was able to inhibit the chaperone activity of Hsc70.
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Figure 2 Intracellular transport of CT
Upon receptor-mediated endocytosis, CT travels in a retrograde fashion to the ER.
Inside the ER, the CTA1 subunit dissociates from the rest of the toxin and unfolds.
CTA1 is then exported to the cytosol where it refolds, then modifies its cytosolic
target, Gs, an activator of AC. Prolonged stimulation of AC leads to an increase
in cAMP which ultimately results in chloride ions (Cl-) being shuttled out of the cell.
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Hsc70 Binding site
To identify the Hsc70 binding site(s) within CTA1, we screened a library of CTA1derived peptides by surface plasmon resonance (SPR). Hsc70 was perfused over
a peptide-coated SPR sensor slide for 180 seconds. The sensor slide was then
washed for an additional 180 seconds after the removal of Hsc70 from the
perfusion buffer. When Hsc70 binds to a peptide an increase in the RIU value is
observed. After washing the slide, the final RIU values are recorded. Hsc70 that
remains bound to the peptide results in an increase in the final RIU value. An
increase in final RIU value was observed for two consecutive peptides spanning
residues 73-98 of CTA1 (Table 3). These two peptides share a core YYIYVI
sequence that most likely represents the Hsc70 binding site. YYIYVI was unable
to be synthesized as a soluble peptide, probably due to its hydrophobic nature, but
there was no observable increase in final RIU values when Hsc70 was perfused
over a GQTILSGHST or ATAPNMNVNDLVG peptide. This suggests Hsc70
recognition is attributed to the core YYIYVI motif found within the extended
sequences. Hsc70 was perfused over a slide coated with a mutant
GQTILSGHSTYYLYVL peptide, containing isoleucine-to-leucine mutations, and
there was no observable increase in final RIU. This indicates Hsc70 did not
recognize the mutant peptide, further confirming the specificity of Hsc70 for the
YYIYVI motif.
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Table 3 Hsc70 recognizes a single region within CTA1
CTA1 residues
1-16

Peptide sequence
NDDKLYRADSRPPDEI

Hsc70 binding
-

11-26

RPPDEIKQSGGLMPRG

-

21-36

GLMPRGQSEYFDRGTQ

-

31-46

FDRGTQMNINLYDHAR

-

41-56

LYDHARGTQTGFVRHD

-

51-66

GFVRHDDGYVSTSISL

-

63-78

SISLRSAHLVGQTILS

-

73-88

GQTILSGHSTYYIYVI

+

83-98

YYIYVIATAPNMFNVN

+

93-108

NMFNVNDVLGAYSPHP

-

103-118

AYSPHPDEQEVSALGG

-

113-128

VSALGGIPYSQIYGWY

-

123-138

QIYGWYRVHFGVLDEQ

-

133-148

GVLDEQLHRNRGYRDR

-

143-158

RGYRDRYYSNLDIAPA

-

153-168

LDIAPAADGYGLAGFP

-

163-177

GLAGFPPEHRAWREE

-

173-188

AWREEPWIHHAPPGCG

-

179-192

WIHHAPPGCGNAPR

-

Peptides were amide-coupled to an SPR sensor slide. Hsc70 was perfused over
the peptide coated SPR sensor slide for 180 seconds before it was removed, and
the sensor slide was washed. Peptides that were recognized by Hsc70 resulted in
an increased final RIU value and are indicated by a (+).
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Table 4 Hsc70 secondary peptide screen.
CTA1 residues
73-82

Peptide sequence
GQTILSGHST

Hsc70 binding
-

83-88

YYIYVI

n.d.

89-102

ATAPNMFNVN

-

73-88

GQTILSGHSTYYLYVL

-

Peptides corresponding to the regions surrounding the core YYIYVI (bold) motif
were appended to an SPR sensor slide. Hsc70 was then perfused over the peptide
coated slide. After removing Hsc70 from the perfusion buffer, the slide was washed
and then the final RIU values were recorded. Hsc70 did not recognize peptides
indicated by a (-) sign. n.d; not determined- the peptide could not be synthesized.
Leucine-for-isoleucine substitutions are shown in red.
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SPR competition assay
An SPR-based competition assay was used to further evaluate the specificity of
the YYIYVI binding site (Figure 3). For this experiment, Hsc70, either alone or in
the presence of peptide, was perfused over an SPR slide coated with full-length
CTA1 for 3 minutes. The slide was then washed with PBS-T before the final RIU
values were recorded. An increase in final RIU was observed for Hsc70 alone and
Hsc70 in the presence of the mutant GQTILSGHSTYYLYVL peptide. There was
no observable increase in final RIU when Hsc70 was added to the perfusion buffer
in the presence of the GQTILSGHGSTYYIYVI peptide. These results suggest that
the YYIYVI/Hsc70 interaction is extremely specific, as mutating the two isoleucine
residues to leucine residues was enough to influence binding of Hsc70 to CTA1.
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Figure 3 Hsc70 competition assay
Full-length CTA1 was appended to an SPR sensor slide. Chaperone alone (no
peptide) or chaperone in the presence of the GQTILSGHSTYYLYVL (YYLYVL) or
GQTILSGHSTYYIYVI(YYIYVI) peptide was added to the perfusion buffer for 180s.
The sensor slide was then washed for an additional 180s and the final RIU values
were recorded.
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Citrate synthase assay
To determine if CTA1 binds within the normal client recognition site of Hsc70, we
evaluated Hsc70 chaperone activity using another competition assay. For this
experiment, chaperone activity is the ability of Hsc70 to protect a client, citrate
synthase, from thermal denaturation. This was evaluated with Hsc70 alone, as well
as with Hsc70 in the presence of peptide. Citrate synthase catalyzes a calorimetric
reaction that allows us to monitor Hsc70 chaperone activity indirectly. We
evaluated citrate synthase activity in the presence of a peptide containing the core
YYIYVI motif (GQTILSGHSTYYIYVI) as well as peptides corresponding to the
regions flanking the core YYIYVI motif (GQTILSGHST and ATAPNMFNVNDVLG).
Additionally, the leucine-for-isoleucine mutant peptide (GQTILSGHSTYYLYVL)
and two previously unrecognized peptides (RPPDEI and LDIAPA) were evaluated
for inhibition of Hsc70 chaperone activity. The GQTILSGHSTYYIVI peptide was
the only peptide shown to significantly impact Hsc70 chaperone activity of citrate
synthase (Figure 4). This confirms YYIYVI is specifically recognized by Hsc70.
Furthermore, the YYIYVI binding site is likely located near or within the normal
client recognition site of Hsc70 as the corresponding peptide was able to partially
inhibit normal Hsc70 chaperone activity.
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*

*

Figure 4 Citrate synthase competition assay
Citrate synthase was heat-denatured at 65C in the presence of Hsc70 or Hsc70
with the indicated peptide. Citrate synthase enzyme activity was assessed
spectrophotometrically using Ellman’s reagent (DTNB). Values shown represent
Hsc70 chaperone activity in the presence of the indicated peptide and are
expressed as a percentage of the chaperone activity of Hsc70 in the presence of
citrate synthase alone (% Maximal Enzyme Activity). 4 replicate samples were
used for each condition, and the data represent averages +/- SEM of at least 4
independent experiments per condition. The asterisk indicates a statistically
significant difference (p<0.045, Student’s t test).
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Discussion
CTA1 exists in a disordered state at physiological temperatures that allows the
toxin A chain to exploit ERAD for its export to the cytosol. The linear CTA1
polypeptide passes through the translocon pore until the N-terminal domain is
recognized by cytosolic chaperone Hsp90 [41, 43]. Refolding of CTA1 is initiated
by Hsp90 which provides the driving force for translocation while also ensuring a
unidirectional movement of CTA1 to the cytosol, as a refolded toxin could no longer
slide backwards through the translocon pore.

Hsp90-driven refolding often occurs in a complex involving Hsc70 [44, 57]. We
have recently reported that cytosolic Hsc70 is also required for CTA1 translocation
to the cytosol [42]. We predict that CTA1 is also refolded by a complex of Hsp90
and Hsc70, as both chaperones are able to induce a gain-of-structure in CTA1.
Additionally, both chaperones are able to

bind to CTA1, independently and

simultaneously, suggesting they most likely recognize distinct regions of CTA1.
Furthermore, we have found that Hsp90 is only able to recognize disordered CTA1
while Hsc70 is able to recognize both the folded and unfolded forms of CTA1 [42].
Based on these results, Hsc70 and Hsp90 must recognize distinct sites within
CTA1.

Hsc70 client discrimination is not yet fully understood. It has been reported that
Hsc70 client recognition is sometimes dictated by co-chaperones [66, 67]. Our
27

work with CTA1 has shown that Hsc70 is able to recognize CTA1 in an atypical
manner that does not require co-chaperones, suggesting a distinct Hsc70 binding
site that is directly recognized by Hsc70 (Table 3) [42]. To date, it is believed that
Hsc70 may recognize a hydrophobic core of 5-7 amino acids within disordered
proteins, but no specific binding motif has been identified [68-70].

This work has identified a single YYIYVI binding motif for Hsc70 within the CTA1
polypeptide spanning residues 83-88. Additionally, results of our chaperone
activity assay confirm that CTA1 is likely recognized within the normal client
binding domain of CTA1, despite the atypical interaction. We predict that Hsc70 is
recruited to assist in the refolding of CTA1 when the YYIYVI motif is exposed on
the cytosolic face of the translocon pore. Together, Hsp90 and Hsc70 ensure
CTA1 translocation to the cytosol while simultaneously ensuring that the
disordered toxin A chain gains, as well as maintains, an active conformation for
the modification of Gs.
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CHAPTER 4: AN HSP90 BINDING MOTIF IN THE A CHAINS OF
ADP-RIBOSYLATING TOXINS THAT MOVE FROM THE ER TO
THE CYTOSOL

Introduction
CT is a prototypical AB-type toxin that consists of a catalytically active A subunit
and a cell binding B subunit [71]. The B homopentamer binds to GM1 on the
surface of host cells which activates receptor mediated endocytosis of the toxin.
CT then travels, via retrograde transport, to the ER where the CTA1 subunit
dissociates from the rest of the toxin and unfolds. ERAD is triggered by the
unfolding event and CTA1 is subsequently exported to the cytosol [50-54, 72].
Cytosolic chaperones Hsp90 and Hsc70 provide the driving force for CTA1
extraction from the ER using a ratchet mechanism that couples translocation and
refolding [42, 43]. Hsp90 then stays associated with CTA1, maintaining CTA1 in
an active conformation for the modification of its g-protein target [42, 73].

In a subset of AB toxins, including diptheria toxin (DT), exposure to the acidic
environment within endosomes causes the B subunit to undergo a conformational
change [74]. A protein-conducting channel is then formed within the endosomal
membrane for the transport of the A chain to the cytosol (Figure 5). Hsp90 has
been implicated in the translocation of several endosome-translocating toxins with
ADP-ribosyltransferase activities [75-81]. Interestingly, Hsp90 does not appear to
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be required for the translocation of endosome-translocating toxins with different
catalytic activities [82, 83]. Additionally, three ER-translocating toxins without ADPribosyltransferase activity do not require Hsp90 for their export to the cytosol [84,
85]. Based on these studies, the Barth lab has predicted that Hsp90 recognizes a
common feature of ADPRTs [86, 87].
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Figure 5 Intracellular trafficking of diptheria toxin (DT)
DT is an E-ADPRT toxin that inhibits protein synthesis. DT enters the cell and
travels within endosomes. The acidic environment of the endosome causes a
conformational change in the DTB subunit, that releases the A subunit from the
rest of the toxin. The B subunit remains embedded within the endosomal
membrane, forming a protein conducting channel, to allow transport of the DTA
subunit to the cytosol. Once inside the cytosol, DT ADP-ribosylates elongation
factor 2 (EF-2), ultimately resulting in a loss of protein synthesis.
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As discussed in Chapter 3, we have determined that Hsc70 recognizes a single
YYIYVI binding site with CTA1 that spans residues 83-88. There are still no specific
binding motifs that have been identified for Hsp90. This work has identified two
distinct binding sites within CTA1, an N-terminal RPPDEI sequence (spanning
residues 11-16) and a C-terminal LDIAPA sequence (spanning residues 153-158).
This is the first time Hsp90 has been shown to bind to specific amino acid
sequences. While the LDIAPA motif was unique to CTA1, we found an RPPDEIlike motif present within the A chains of several other ER-translocating toxins with
ADP-ribosyltransferase activity. ER-translocating toxins with other catalytic
activities, as well as endosome-translocating toxins with ADP-ribosyltransferase
activity, lack an RPPDEI-like motif suggesting Hsp90 most likely interacts with a
different feature of ADPRTs that move from the endosome to the cytosol.

Based on the locations of the Hsp90 and Hsc70 binding sites within the CTA1
polypeptide, we predict that CTA1 exits the ER in an N- to C-terminal fashion.
Hsp90 recognizes the RPPDEI motif within CTA1 as it exits the translocon pore.
ATP-dependent refolding by Hsp90 is then initiated, which provides the driving
force for toxin extraction to the cytosol. Hsc70 subsequently binds to partially
refolded CTA1 as the YYIYVI motif is exposed. Hsp90 then interacts with CTA1 a
second time, via the C-terminal LDIAPA motif, and together the two chaperones
work to ensure CTA1 gains, as well as maintains, an active conformation for
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modification of its cytosolic target. With the identification of the Hsp90 binding sites,
this work has determined the directionality of CTA1 export to the cytosol.
Additionally, we have identified an atypical Hsp90 interaction, providing insight into
chaperone biology.

Hsp90 binding sites
To identify the Hsp90 binding site(s) in CTA1, a peptide library, spanning the entire
amino acid sequence of CTA1, was synthesized and screened by SPR for
interactions with Hsp90. For these experiments, Hsp90/ATP was perfused over a
peptide-coated SPR sensor slide for 180 seconds. Hsp90 was removed from the
perfusion buffer, and the slide was then washed with PBS-T for an additional 180
seconds before final RIU values were recorded. Chaperone binding to the peptide
would result in an increase in the final RIU values. An increase in final RIU value
was observed for two sets of consecutive peptides within two distinct regions of
CTA1, spanning residues 1-26 and 143-168 as seen in Table 5. We predicted the
core RPPDEI and LDIAPA sequences most likely represented the binding sites as
those sequences were shared between the consecutive peptides. A secondary
library of peptides was generated containing sequences that corresponded to the
core sequences as well as the sequences flanking the core amino acids (Table 6).
An RPPDEI-peptide was recognized by Hsp90, but neither of the peptides
corresponding to the NDDKLYRADS or KQSGGLMPRGG flanking sequences
were recognized by Hsp90. These results suggest that Hsp90 recognizes an N33

terminal RPPDEI motif within CTA1. Unfortunately, LDIAPA was unable to be
synthesized as a soluble peptide. However, Hsp90 was unable to bind to either of
the flanking sequences, RGYRDRYYSN and ADGYGLAGFP, indicating that the
core sequence must account for Hsp90 binding in both of the extended peptide
sequences containing LDIAPA. Hsp90 was unable to recognize any peptide in the
absence of ATP (not shown). Based on these results, we concluded that Hsp90
recognizes two distinct regions within CTA1. Furthermore, we have identified
RPPDEI and LDIAPA as the specific binding motifs for Hsp90 within CTA1.
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Table 5 Hsp90 binding sites within CTA1
CTA1 residues
1-16

Peptide sequence
NDDKLYRADSRPPDEI

Hsp90 binding
+

11-26

RPPDEIKQSGGLMPRG

+

21-36

GLMPRGQSEYFDRGTQ

-

31-46

FDRGTQMNINLYDHAR

-

41-56

LYDHARGTQTGFVRHD

-

51-66

GFVRHDDGYVSTSISL

-

63-78

SISLRSAHLVGQTILS

-

73-88

GQTILSGHSTYYIYVI

-

83-98

YYIYVIATAPNMFNVN

-

93-108

NMFNVNDVLGAYSPHP

-

103-118

AYSPHPDEQEVSALGG

-

113-128

VSALGGIPYSQIYGWY

-

123-138

QIYGWYRVHFGVLDEQ

-

133-148

GVLDEQLHRNRGYRDR

-

143-158

RGYRDRYYSNLDIAPA

+

153-168

LDIAPAADGYGLAGFP

+

163-177

GLAGFPPEHRAWREE

-

173-188

AWREEPWIHHAPPGCG

-

179-192

WIHHAPPGCGNAPR

-

A CTA1-derived peptide library was screened for Hsp90 recognition using SPR.
Hsp90 was perfused over an SPR slide coated with a CTA1-derived peptide. After
removal of Hsp90 from the perfusion buffer, the slide was washed. Peptides that
were recognized by Hsp90 are indicated by a (+) sign. Hsp90 was unable to bind
to any peptide in the absence of ATP (not shown).
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Table 6 Hsp90 secondary screen
CTA1 residues
1-10

Peptide sequence
NDDKLYRADS

Hsp90 binding
-

11-16

RPPDEI

+

17-26

KQSGGLMPRGG

-

143-152

RGYRDRYYSN

-

153-158

LDIAPA

n.d.

159-168

ADGYGLAGFP

-

SPR was used to screen peptides corresponding to the core binding motifs (bold)
as well as the regions flanking the RPPDEI and LDIAPA sequences. Each peptide
was appended to an SPR sensor and exposed to Hsp90/ATP. Binding is indicated
by a (+) sign. Hsp90 was unable to bind to RPPDEI in the absence of ATP (not
shown). n.d.; not determined - the peptide could not be synthesized.
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SPR competition assay
To confirm the specificity of the Hsp90 binding sites, we used an SPR-based
competition assay (Figure 6). For this experiment, full-length CTA1 was appended
to the sensor slide. Hsp90 was then perfused over the slide for 3 minutes before it
was removed from the perfusion buffer. The slide was then washed with PBS-T for
an additional 3 minutes before the final RIU value was recorded. An increase in
final RIU value indicates that Hsp90 bound to the CTA1-coated sensor slide. We
observed an increase in final RIU value when Hsp90 was perfused over CTA1 in
the absence of peptide. In the presence of a CTA1 peptide, containing the Hsc70
binding site sequence (YYIYVI), a similar trace was observed. The addition of
RPPDEI or LDIAPA-containing peptides resulted in a loss of Hsp90 binding to full
length CTA1 as indicated by the near return to baseline RIU values. This
demonstrates that Hsp90 specifically recognizes the RPPDEI and LDIAPA motifs
within CTA1, as both peptides were able to occlude the CTA1 binding pocket within
Hsp90. In chapter 3, we discuss the identification of a single Hsc70 binding site,
YYIYVI, within CTA1. While a YYIYVI-containing peptide was able to effectively
inhibit Hsc70 binding to full-length CTA1 (Figure 3), Hsp90 binding to CTA1 was
not influenced by the presence of the YYIYVI-containing peptide (Figure 6). This
result further confirms the specificity of Hsp90 for the RPPDEI and LDIAPA binding
sites within CTA1.
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Figure 6 Hsp90 competition assay
Full-length CTA1 was appended to an SPR sensor slide. Hsp90/ATP was perfused
over the CTA1-coated sensor slide alone, or in the presence of a 2-fold molar
excess of the indicated peptide, for 180s. Peptides tested contained either an
Hsc70 binding site sequence, GQTILSGHSTYYIYVI (YYIYVI), or an Hsp90
binding site sequence, RPPDEI or RGYRDRYYSNLDIAPA (LDIAPA). The slide
was then washed for an additional 180s with PBS-T before the final RIU values
were recorded.

38

Role of Hsp90 in CTA1 translocation
There is a possibility that one, or both, of the identified Hsp90 binding sites are not
involved in the translocation of CTA1 but rather in a separate interaction with
Hsp90. To test this theory, we transfected CHO cells with an ER-localizing variant
of CTA1 (ssCTA1) that allows us to look at ER-to-cytosol translocation,
independent of the upstream trafficking and disassembly events. ssCTA1 contains
an N-terminal signal sequence that targets it for co-translational insertion into the
ER. The signal sequence is cleaved by a resident ER peptidase once inside the
ER then CTA1 follows its normal ERAD-mediated pathway to the cytosol [47].
Transfected cells were permeabilized using digitonin before the membrane (pellet,
P) fraction was separated from the cytosolic (supernatant, S) fraction. Fractions
were then analyzed by Western blot for the presence of CTA1 (Figure 7). Cells
transfected with ssCTA1 showed the presence of CTA1 in both the membrane and
cytosolic fractions, indicating that translocation had occurred.

Site-directed-mutagenesis was used to create truncated variants of ssCTA1 that
lacked the previously-identified Hsp90 binding sites. No CTA1 was detected in the
cytosol of CHO cells transfected with N- or C-terminal truncations of ssCTA1,
lacking the RPPDEI or the LDIAPA binding sites (Figure 7). Based on these results
we concluded that both the RPPDEI and LDIAPA regions are required for CTA1
export to the cytosol. It’s been previously reported that the CTA1(3) subdomain,
spanning residues 170-192 and containing neither Hsp90 or Hsc70 binding sites,
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is required for CTA1 activity but not for translocation [88]. We also show that the
CTA1(3) subdomain is not required for translocation as the CTA1(3) truncation
was observed within the cytosol of transfected cells (Figure 7).
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Figure 7 ssCTA1 ER-targeted translocation assay
CHO cells were transfected with pcDNA3.1 (mock) or pcDNA3.1/ssCTA1 (CTA1).
The membrane (Pellet, P) and cytosolic (supernatant, S) fractions of digitonin
permeabilized cells were then probed for the presence of CTA1 by Western blot.
Results for truncated versions of CTA1 lacking the RPPDEI binding site (CTA117192),

the LDIAPA binding site (CTA11-133), and the A1(3) subdomains (CTA11-169)

are shown.
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An Hsp90 binding motif in ER-translocating ADPRTs
It has been suggested that Hsp90 recognizes a conserved feature of ADPRTs so
we looked for an N-terminal RPPDEI-like motif in the A chains of other ERtranslocating toxins [87]. The motif was present found to be present (Table 7) in
Escherichia coli heat-labile toxin (LT), pertussis toxin (PT), and Salmonella
Typhimurium ADPRT (ArtAB). The A chain of Pseudomonas aeruginosa exotoxin
A (ETA), Shiga toxin 1 (ST1), Shiga toxin 2 (ST2), and ricin (RT) do not contain an
N-terminal RPPDEI-like motif. ETA is an ADP-ribosylating toxin, but the other three
toxins lacking the RPPDEI-like motif are not. Our SPR screen was used to
determine if Hsp90 recognizes the N-terminal regions of any of the ERtranslocating toxins in Table 7. We observed Hsp90 binding to LT, PT, and ArtAB
peptides but not to ETA, ST1, ST2, or RT peptides. This result indicates that Hsp90
only recognizes the N-terminal regions of ER-translocating toxins with an RPPDEIlike motif present. A chains containing the Hsp90 binding motif are all ADPRTs, so
we conclude that Hsp90 recognizes a common RPPDEI-like motif within the A
chains of ER-translocating ADPRTs (ER-ADPRTs).

42

Table 7 N-terminal sequences of ER-translocating toxins
ADPRTs:
CT
LT
PT
ArtAB
ETA

1-16
1-16
1-18
1-16
1-16

Other toxins:
ST1
1-16
ST2
1-16
RT
1-16

NDDKLYRADSRPPDEI
NGDRLYRADSRPPDEI
DDPPATVYRYDSRPPEDV
VDFVRYVDSRPPDVIF
AEEAFDLWNECAKACV

Hsp90 binding
+
+
+
+
-

KEFTLDFSTAKTYVDS
REFTIDFSTAQQYVSS
IFPKQYPIINFTTAGA

Hsp90 binding
-

The N-terminal regions of the A chains of several ER-translocating toxins were
analyzed for the presence of an RPPDEI-like motif (bold). Each peptide was
evaluated for recognition by Hsp90 using our SPR binding assay. Peptides
recognized by Hsp90 are denoted with a (+) and peptides that did not interact with
Hsp90 are denoted with a (-). Hsp90 did not bind to any peptides in the absence
of ATP (not shown).
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We considered there may be Hsp90 binding sites present within other regions of
the toxin A chains, so we examined the entire length of each toxin A chain for
additional Hsp90 binding sites. LTA1, which shares 86% identity with CTA1,
contains an LNIAPA motif but no other toxins had an LDIAPA motif present. No
other toxin A chains appeared to have an internal N-to-C-terminal RPPDEI-like
motif. The A chain of ETA contains a C-terminal RPPDEI-like motif in the reversed
orientation: PGKPPREDL (Figure 8). Hsp90 recognized the C-terminal peptide of
ETA, PGKPPREDL, in an ATP-dependent manner using our SPR-based assay
(Figure 8).
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A)

Hsp90 binding
ETA

622-637

LPDYASQPGKPPREDL

+

ETA

637-622

LDERPPKGPQSAYDPL

+

B)

RIU

Hsp90
+ATP

Hsp90

Time (s)

Figure 8 Exotoxin A
A) Exotoxin A contains an RPPDEI-like motif in the reverse order (bold). A peptide
corresponding to this region was screened for recognition by Hsp90 using SPR.
Peptides recognized by Hsp90 are indicated by a (+) sign. A KDEL-like sequence
present within ETA is underlined. B) Hsp90/ATP was perfused over a ETA-derived
peptide-coated slide. Hsp90 was then removed from the buffer and the slide was
washed. No peptide was recognized in the absence of ATP.
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Endosome-translocating toxins
Remarkably the A chains of endosome-translocating ADPRTs (E-ADPRTs) do not
contain an RPPDEI-like motif even though they’ve been shown to require Hsp90
for translocation (Table 8). The LDIAPA motif was also not found in any of the
endosome-translocating toxins so the mechanism of recognition must be different
for endosome-translocating that require Hsp90 for translocation to the cytosol. It
should be noted that E-ADPRTs often require prolyl isomerases (PIs), like
cyclophilin A (CypA), for their activity suggesting Hsp90 may require different cochaperones for the export endosome-translocating toxins than is seen with CTA1
translocation, which does not require PIs [42].
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Table 8 Endosome translocating toxins

Toxin:
Diptheria toxin

ADPRT
+

Hsp90-dependent
+

Ref
[72, 77, 78]

Clostridium perfringens iota toxin

+

+

[ 73, 74]

Clostridium difficile CDT toxin

+

+

[ 73, 74]

Photorhabdus luminescens PTC3

+

+

[ 75]

Clostridium botulinum C2 neurotoxins

+

+

[71 ]

Botulinum and tetanus neurotoxins

-

+

[ 76]

Clostridium difficile TcdA and TcdB toxins

-

-

[ 79]

Bacillus anthracis lethal factor

-

-

[78 ]

Toxins with an ADP-ribosyltransferase activity are denoted with a (+). Toxins that
require Hsp90 are denoted with a (+). None of these toxins contain the RPPDEI or
LDIAPA binding motifs for Hsp90 that were identified in CTA1.
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Identification of key residues in the RPPDEI binding motif

The RPP residues are conserved across all the RPPDEI-like motifs within ERADPRTs (Figure 8 and Table 7). To determine which, if any, of these residues are
essential to translocation we introduced valine substitutions into each of the RPP
residues using our ssCTA1 construct. We then evaluated the effect that each point
mutation had on translocation using our targeted translocation assay. A mutation
of the arginine to a valine (RPP  VPP) resulted in a loss of CTA1 signal for all
cellular fractions (not shown) indicating a loss of ssCTA1 expression. A mutation
of the arginine to a threonine (RPP  TPP) restored expression of ssCTA1, as
evidenced by the presence of CTA1 in the membrane fraction (Figure 9). The TPP
mutation was not able to restore translocation, as evidenced by the lack of CTA1
present in the cytosol (Figure 9). Additionally, valine substitutions for either of the
prolines blocked export of CTA1 to the cytosol (Figure 9). Collectively these results
indicate that all three of the conserved RPP residues are required for translocation
of CTA1 to the cytosol. It is possible that the arginine plays a role in translation in
addition to its role in translocation, perhaps by influencing ribosome stalling [8991].
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Figure 9 Point mutations in ssCTA1
Point mutations were created in the RPP residues of ssCTA1. CHO cells were then
transfected with the indicated constructs. The membrane (pellet, P) and cytosolic
(supernatant, S) fractions of digitonin-permeabilized cells were then evaluated for
the presence of CTA1 via Western blot. Data is representative of at least 3 replicate
experiments.
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Discussion
Hsp90 is linked to many functions within the cell, all involving different client
proteins [44]. Hsp90 demonstrates a higher client specificity than other chaperones
[92, 93] but has not yet been shown to recognize any specific motif. It is widely
accepted that Hsp90 client recognition is dictated by co-chaperones, however, we
have shown that Hsp90 is able to bind to RPPDEI and LDIAPA amino acid
sequences within CTA1, without the need for co-chaperones (Table 5 & Table 6).
Additionally, we have demonstrated, using a competition assay, that the two
different binding sequences likely occupy the same binding pocket within Hsp90.
Peptides corresponding to either sequence were sufficient to occlude the binding
pocket and prevent Hsp90 binding to full-length CTA1 (Figure 6).

Hsp90 has been implicated in the cellular activity of other ER- ADPRTs [85, 94].
These toxins share an RPPDEI-like motif within their A subunits that is recognized
by Hsp90 (Table 7). CTA1 requires both the RPPDEI motif, as well as Hsp90, for
its translocation to the cytosol (Figure 7) [41, 43]. PTS1, another ER-ADPRT, is
recognized directly by Hsp90 [94] and we believe that Hsp90 recognizes the
RPPDEI-like motif found within the N-terminal region of PTS1 (Figure 8 and Table
7). We predict accordingly, that PTS1 follows a similar translocation pathway to
CTA1 and that both Hsp90 and the RPPDEI-like motif are required for the
extraction of PTS1 to the cytosol. A role has already been established for Hsp90
in ETA intoxication [85], another ER-ADPRT containing an RPPDEI-like motif, and
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we predict this toxin A chain also utilizes an RPPDEI-like motif for its Hsp90-driven
extraction to the cytosol. The ER-to-cytosol translocation pathway exploited by
ArtAB has yet to be established [95], but based on the presence of an RPPDVI
motif within its toxin A chain, we predict that ArtAB will also follow a similar Hsp90driven pathway for its export from the ER to the cytosol.

Within the A chains of CT, LT, PT, and ArtAB we found 4 additional conserved
residues (YRxDS, CTA16-10). These residues could be part of an extended
YRxDSRPPDEI binding motif for Hsp90 within CTA1 (Table 7). It should be noted
that some of these residues are also involved in the catalytic activity of toxin A
chains. Both CT and PT require arginine and aspartic acid residues present within
the YRxDS motif for modification of their cellular targets [96-100]. Additional work
has shown that PTS1 activity requires the arginine of the RPPDEI motif [96]
suggesting the N-terminal sequences may be conserved for Hsp90 binding,
enzymatic activity, or both. Interestingly, ETA lacks the YR residues conserved in
other toxins (Figure 8) suggesting those residues most likely play a role outside of
the ER-to-cytosol translocation of toxin A chains. Furthermore, we have
demonstrated that the RPPDEI motif is recognized directly by Hsp90 and is
sufficient to block binding to full-length CTA1, without the extended YRxDS
residues. Therefore, we conclude that RPPDEI likely represents the core Hsp90
binding site.
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ETA is the only toxin A chain that contains an RPPDEI-like motif, RPPKGP, at its
C-terminus (Figure 8). The arginine within the RPPKGP motif has been previously
reported to be involved with ETA intracellular trafficking [101]. Specifically, an
REDL sequence was identified that functions as an inefficient binding motif for the
host KDEL receptor and is required for ETA activity. Remarkably, ETA is able to
exploit a retrograde transport pathway that does not utilize a KDEL receptor [102].
We predict that the REDL sequence is linked to Hsp90-driven translocation, in
addition to intracellular trafficking. The need for a high affinity Hsp90 binding site
has led to the selection of an REDL sequence, over the much more efficient KDEL
sequence, by ETA to ensure ETA is effectively delivered to the cytosol.

Extensive studies with endosome-translocating toxins has led to the prediction that
Hsp90 is involved in the translocation of all ADPRTs to the cytosol [86, 87].
Furthermore, it has been suggested that Hsp90 recognizes a common feature of
E-ADPRTs. Our work supports this idea and expands it to include ER-ADPRTs as
well [41, 43, 85]. We have identified an Hsp90 binding site within the A chains of
ER-ADPRTs. A similar motif is not found in any toxin A chains with different
catalytic activities. Remarkably, the RPPDEI sequence appears to be absent from
E-ADPRTS as well, suggesting that Hsp90 recognizes a different feature of
ADPRT A chains that move from endosomes to the cytosol. We predict that the
molecular details of Hsp90-driven toxin export must differ between E-ADPRTs and
ER-ADPRTs. Additional support for this idea comes from the requirement of prolyl
cis/trans isomerases for the export of E-ADPRTs, but not CTA1 [42, 86, 87].
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Surprisingly, PTS1 requires prolyl cis/trans isomerase activity for its productive
intoxication as well [103], suggesting that although we’ve identified a common role
for Hsp90 in ER-ADPRTs, toxin-to-toxin variability influences the involvement of
co-chaperones, such as PIs, in toxin translocation.

AB toxins, both endosome-translocating and ER-translocating, are commonly
modified to enhance the delivery of drugs to the cytosol of cells [104, 105].
Additional toxin components have been modified to enhance the delivery of
immunogenic proteins to the cytosol for MHC class I presentation [106]. Typically,
the toxin A chain is replaced with a recombinant protein that utilizes the cell-binding
B subunit for its entry into the cell. Unfortunately, efficient delivery of the cargo from
the endosomes, or the ER, to the cytosol is not guaranteed using this method.
Based on our work, we predict that the addition of an N-terminal RPPDEI sequence
to ER-localizing cargo will enhance delivery to the cytosol via an Hsp90-driven
translocation mechanism.

As CTA1 exits the ER, it is in a linearized state. Because of this we used peptides
to screen for Hsp90 binding sites within CTA1, mimicking the linear amino acid
sequence of CTA1 as it exits the ER. Based on the proximity of the RPPDEI motif
to the N-terminus of CTA1, we predict that CTA1 first encounters Hsp90 as it exits
the ER. Accordingly, CTA1 must exit the ER in an N-to-C-terminal fashion. Hsp90
recognizes the RPPDEI motif as it is exposed on the cytosolic face of the ER
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translocon pore. Refolding is then initiated by Hsp90 which provides the driving
force for CTA1 translocation to the cytosol [43]. Hsc70 is recruited to the partially
folded CTA1 polypeptide, as the previously identified YYIYVI motif is exposed
(Chapter 3). Hsp90 then interacts with CTA1 again at the LDIAPA binding site, and
together the two chaperones ensure that CTA1 not only gains, but maintains, the
active conformation required for ADP-ribosylation of its cytosolic target.

Consistent with our model of N-to-C-terminal directionality of CTA1 export, a
truncation of the C-terminal subdomain, CTA1169-192, does not effect CTA1
translocation to the cytosol (Figure 7) [88]. Notably, no Hsp90 or Hsc70 binding
sites were missing in this truncation. Further truncations, lacking either the LDIAPA
or RPPDEI motifs, rendered CTA1 unable to move from the ER to the cytosol
(Figure 7). Based on these results, we conclude that both Hsp90 binding sites are
required for CTA1 translocation from the ER to the cytosol.
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CHAPTER 5 PERTUSSIS TOXIN
Introduction
Pertussis toxin (PT) is an AB5 toxin (Figure 1 and Figure 10) that has a catalytic
S1 (PTS1) subunit that is noncovalently linked to a cell-binding B pentamer. The
B pentamer consists of an S5 monomer that links together two dimers consisting
of S2/S4 subunits and S3/S4 subunits (Figure 10). PT recognizes multiple
receptors, most likely due to the binding sites for sialic acid within the S2 and S3
subunits [25, 107-110]. Upon receptor-mediated endocytosis, PT travels to the ER
using retrograde transport (Figure 11). Inside the ER, the S1 subunit dissociates
from the rest of the toxin and unfolds. Most ER-translocating toxins have disulfide
bonds that are reduced inside the ER, but PT has no disulfide bonds linking the
catalytic subunit to the rest of the toxin and, therefore, follows a different
disassembly mechanism. ATP binds to the central pore of the B pentamer of PT,
which causes a conformational change that releases the S1 subunit from the rest
of the toxin [111-114]. A reduction of intramolecular disulfide bonds in PTS1
follows, which allows the toxin to unfold [115, 116] . The disordered PTS1 subunit
is then exported via ERAD to the cytosol [117, 118], although it is still unclear which
ERAD factors are responsible for delivery of PTS1 to the cytosol.

Native ERAD substrates are exported to the cytosol to be degraded, but PTS1’s
arginine-for-lysine bias allows it to escape ubiquitination, required for recognition
by the 26S proteasome [118-124]. The toxin is then refolded by host factors, an
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event that is poorly understood, to an active conformation to ADP-ribosylate its Gi
target [118, 125-127]. This modification inactivates Gi, so the activity of adenylate
cyclase can no longer be inhibited, ultimately resulting in elevated levels of cAMP
within the cell and dysregulation of signal transduction (Figure 11). The events and
molecular chaperones involved in translocation, and subsequent reactivation of
PTS1 within the cytosol, remain to be identified.
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Figure 10 PT structure
Ribbon diagram based on the crystal structure (PDB 1PRT) of pertussis toxin. The
catalytic S1 subunit is shown in cyan. The B pentamer is composed of S2 (purple),
S3(pink), two S4 subunits (blue), and an S5 subunit (green).
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Figure 11 PT trafficking
A schematic representation of PT trafficking through the cell. Upon entry into the
cell, PT travels to the ER where the S1 subunit dissociates from the rest of the
toxin before exiting the ER to modify its cytosolic G protein target (Gi). Prolonged
stimulation of adenylate cyclase (AC) results in elevated cAMP levels, that
ultimately lead to signaling dysfunction within the cell.
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Hsp90 involvement with PT
It is unclear which host factors are responsible for extraction and refolding of PTS1
on the cytosolic face of the ER. Cytosolic chaperone Hsp90 has been implicated
in the activity of several ADPRTs [43, 78, 79, 86, 87], and it has been suggested
that Hsp90 may play a general role in the translocation of all ADPRTs [103]. Our
lab has demonstrated Hsp90 is required for translocation of CTA1 across the ER
membrane [41, 87]. Furthermore, we have identified two distinct Hsp90 binding
sites within CTA1 (Chapter 4). Within the N-terminal RPPDEI binding site of CTA1,
a core RPP motif is present that is conserved in the A chains of ADPRTs that travel
to the cytosol via the ER (Table 7 and Table 8). PTS1 contains and RPPEDV motif
that is recognized by Hsp90, suggesting Hsp90 employs a similar strategy of toxin
extraction coupled to chaperone-induced refolding of PTS1, as seen with CTA1.
Geldanamycin (GA), an Hsp90 inhibitor, was used in conjunction with our targeted
translocation assay to assess the role of Hsp90 in the translocation of PTS1. For
this experiment, CHO cells were transfected with ssPTS1, an ER-localizing variant
of PTS1, and then exposed to 10 M GA. Cells were collected 24 hours posttransfection and then permeabilized using digitonin. Cells were separated into
membrane and cytosolic fractions by centrifugation, and the fractions were then
analyzed using a Western blot. PTS1 was observed in the cytosol of untreated
cells, but GA treatment resulted in a loss of PTS1 translocation to the cytosol
(Figure 12). The effects of GA treatment on CT intoxication are established, so
CTA1 was used as a control [41, 43]. Based on these results, we believe that
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Hsp90 is involved with PT intoxication and, furthermore, that the involvement is at
the level of PTS1 translocation to the cytosol.

60

+GA

Figure 12 GA effects on translocation of CTA1 and PTS1
CHO cells were transfected with ER-localizing variants of CTA1 or PTS1 and then
exposed to GA treatment. After an overnight incubation, cells were separated by
digitonin permeabilization into membrane (pellet, P) and cytosol (supernatant, S)
fractions. The fractions were analyzed by Western blot using either -CT or -PT
antibodies. Membranes were then washed before being incubated with HRPconjugated goat -rabbit antibodies. Western blots were developed using
chemiluminescence (ECL).
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Cyclophilins
The role of cyclophilins in E-ADPRT activity is well documented [82, 86, 87]. The
Barth lab has recently published that cyclophilins are required for PT intoxication
as well [103]. Cyclophilins could be involved in multiple steps of intoxication, but
we wanted to know if it is at the level of translocation. We used cyclosporin A, a
general cyclophilin inhibitor, to treat CHO cells transfected with ssPTS1. Cells were
then permeabilized by digitonin and separated into cellular fractions that were
analyzed by Western blot. Cyclosporin A (CysA) blocked PTS1 translocation to the
cytosol, as evidenced by the lack of PTS1 in the cytosol (Figure 13), indicating
cyclophilin involvement in PTS1 translocation. ER-resident cyclophilin B (CypB) is
required for the productive export of some ERAD substrates [128], specifically
those with proline residues in a cis conformation. The Hsp90 binding site found
within PTS1 contains two proline residues (Table 7). Proline residues readily
undergo isomerization events, further discussed in Chapter 6, so it is likely that
one, or both prolines, is in a conformation recognized by CypB. Therefore, I predict
CypB is the CysA-sensitive ERAD factor required for PTS1 activity in the Barth lab
study [103].
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Figure 13 Role of ERAD factors in PTS1 translocation
CHO cells were transfected with ssPTS1, an ER-localizing variant of PTS1.
Following transfection, cells were incubated in the presence of no drug (PTS1),
cyclosporine A (CysA), pfithrin- (Pf), NMS-873, Eeyarestatin I (EerI), or DBeQ.
CysA is a general cyclophilin inhibitor. Pf inhibits Hsp70 family members. NMS873, EerI, and DBeQ are p97 inhibitors. After an overnight incubation, cells were
separated into membrane (pellet, P) and cytosolic (supernatant, S) fractions. The
fractions were probed by Western blot using an -PT antibody. Blots were then
exposed to HRP-conjugated goat -rabbit antibodies and then developed using
ECL.
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Hsc70
CTA1 requires Hsc70, in addition to Hsp90, for translocation so naturally we
examined whether Hsc70 was required for translocation of PTS1 as well. To
investigate Hsc70 involvement we transfected CHO cells with ssPTS1. After an
overnight incubation with Hsc70 inhibitor Pifithrin- (Pf), cells were separated into
membrane (pellet, P) and cytosolic (supernatant, S) fractions. Cellular fractions
were analyzed via Western blot for the presence of PTS1. Pf treated cells showed
a dramatic decrease in PTS1 across all fractions, indicating weak protein
expression (Figure 13). We concluded that pharmacological Hsc70 inhibitors are
likely not compatible with our targeted-translocation assay, as evidenced by the
loss of expression. Our targeted-translocation assay relies on co-translational
insertion of PTS1 into the ER. The ribosome provides the initial driving force for
insertion, but ER factors must provide to driving force to complete the process. ERresident BiP is an Hsp70 family that is responsible for driving many processes
within the ER, including co-translational insertion [129-131]. I predict that the loss
of PTS1 expression we observed in Pf treated cells was a result of blocking BiP
activity, and blocking co-translational insertion.

SPR results indicate that Hsc70 is able to recognize CTA1 but not PTS1 (Table 9),
suggesting Hsc70 most likely does not play a role in the translocation of PTS1. We
identified a YYIYVI motif for Hsc70 within CTA1, whereas PTS1 has a GYIYEV
motif (Table 9), so we predicted one or more of the non-conserved residues (G, E,
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V) in the GYIYEV motif must be responsible for the loss of interaction between
Hsc70 and PTS1. CTA1-derived peptides containing the CTA1-to-PTS1 mutations
were screened by SPR for Hsc70 binding. An SPR sensor slide was first coated
with peptide, then Hsc70 was perfused over the peptide-coated slide for 3 minutes.
Hsc70 was then removed from the buffer, and the sensor slide was washed for an
additional 3 minutes. Final RIU values were recorded. Increased final RIU values
were observed for the peptide containing the Y83G mutation, indicating Hsc70 was
able to recognize that peptide. This was not the case for the V87E mutation,
indicating that the valine residue at position 87 within CTA1 plays a crucial role in
Hsc70 binding to CTA1. Taken together, these results suggest that Hsc70 is able
to discriminate between CT and PT based on a single amino acid difference,
changing a hydrophobic V residue for a charged E in the YYIYVI binding motif for
Hsc70. This suggests that an E to V substitution within PTS1 could create of a
gain-of-binding, although this has not yet been tested.
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Table 9 CTA1 to PTS1 mutations affect Hsc70 binding

CTA1
PTS1

Residues
73-88
76-91

Peptide sequence
GQTILSSGHSTYYIYVI
ERAGRGTGHFIGYIYEV

Hsc70 binding
+
-

CTA1
CTA1
CTA1

73-88
73-88
73-88

GQTILSGHSTGYIYVI
GQTILSGHSTYYIYEI
GQTILSGHSTYYIYVV

+
n.d.

CTA1 and PTS1-derived peptides were screened by SPR for an interaction with
Hsc70. Chaperone was perfused over a peptide coated slide for 3 minutes then it
was removed from the perfusion buffer. The slide was then washed for an
additional 3 minutes. Peptides recognized by Hsc70 are indicated by a (+) sign.
The Hsc70 binding site within CTA1, as well as a similar sequence within PTS1,
are indicated in bold. PTS1-for-CTA1 mutations are indicated in red. n.d.; not
determined – the peptide could not be coupled to the SPR sensor slide.
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p97, an AAA+ ATPase
p97 is a member of the AAA+ ATPase family that serves a vital role in the
retrotranslocation of ERAD substrates to the cytosol. Typically, substrates that are
extracted in a p97-dependent fashion are ubiquitinated [132]. CTA1 has evolved
an arginine-over-lysine bias to escape ubiquitination [41]. Like CTA1, PTS1 lacks
the lysine residues required for ubiquitination [124]. It is widely accepted that p97
does not play a role in CTA1 translocation to the cytosol [39, 41, 133]. Instead,
Hsp90 provides the driving force for CTA1 extraction from the cytosol, using a
ratchet mechanism that couples toxin extraction with refolding [41-43]. CTA1
translocation relies on Hsp90 binding sites, as discussed in Chapter 4. One of the
Hsp90 binding sites, RPPDEI, is partially conserved across other ER-ADPRTs,
including PTS1. As such, we predicted that PTS1 translocation would occur in an
Hsp90-dependent fashion that does not require p97 activity.

NMS-873 blocks Hsp90 activity and p97 activity at a concentration of 10 M but
blocks p97 alone at lower concentrations. We accordingly predicted we would see
a block in translocation at high but not low concentrations of NMS-873. We actually
saw a block at both concentrations, so PT may employ a unique translocation
mechanism that is mediated by both Hsp90 and p97 (Figure 13). Another
possibility is that NMS-873 also blocks Hsp90 at low concentrations, as a very
limited number of studies have been conducted on the effects of NMS-873 on
Hsp90. Additionally, we tested the effects of two other p97 inhibitors, Eeyarestatin
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I (EerI) and N,N'-Dibenzylquinazoline-2,4-diamine (DBeQ), on PTS1 translocation
to the cytosol using our targeted-translocation system (Figure 13). Both of these
pharmacological inhibitors act on the ATPase domain of p97. Because we’ve
established PTS1 translocation is driven by Hsp90, we predicted that neither p97
inhibitor would have an effect on translocation as it is likely a p97-independent
process. Remarkably, we observed a block in PTS1 translocation for cells treated
with DBeQ, but not for cells treated with EerI. NMS-873, DBeQ, and EerI are all
marketed as p97-specific inhibitors that act by inhibiting ATP hydrolysis. Based on
our results, we believe that some of these p97-specific inhibitors may have a
greater effect on other chaperones than previously thought. More studies need to
be conducted to determine the effects of p97 inhibitors on other closely related
chaperones. To further investigate the role of p97 in PTS1 translocation, other
approaches, such as RNAi or p97 inactivating mutations, should be considered.
Based on our results we believe PTS1 translocation is an Hsp90-driven process,
but we cannot definitively say that p97 is not involved at this time.

Discussion

The presence of a shared RPPDEI motif in ER-ADPRTs suggests a common role
for Hsp90 in the translocation of all of these toxins (Chapter 4). The role of Hsp90
in CTA1 translocation has been well documented and preliminary data suggest
that Hsp90 serves a similar role in ETA intoxication [85]. Hsp90 binds directly to
PTS1 in an ATP-dependent manner [94], most likely to its RPPDEI-like motif, and
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probably facilitates a similar ratchet mechanism of Hsp90-mediated translocation.
We used our targeted translocation assay to confirm that Hsp90 is required for
PTS1 translocation to the cytosol(Figure 12).

Hsc70 binds to a YYIYVI motif within CTA1 and assists with Hsp90-driven
extraction of CTA1 to the cytosol (Chapter 3) [42]. PTS1 relies on an Hsp90-driven
extraction mechanism (Figure 12), and contains a GYIYEV motif (Table 9), so we
predicted that Hsc70 plays a role in PTS1 translocation as well. Our targeted
translocation assay was not compatible with pharmacological Hsc70 inhibitors, so
we looked for a direct interaction between Hsc70 and PTS1 using SPR. Results
indicated that while Hsc70 is able to recognize a YYIYVI motif within CTA1, a
similar GYIYEV found within PTS1 is not recognized by SPR. Further SPR studies
revealed Hsc70 is able to distinguish between the two toxin A chains based on a
single amino acid difference at position 87 (Table 9). There is a third amino acid at
position 88 that was not tested for an interaction with Hsc70, because it was
incompatible with our SPR-coupling procedure. Future studies should consider
utilizing full-length toxin A chains containing the desired mutations in the place of
mutant peptides. Using full-length proteins would most likely abolish the SPRcoupling issues we observed with some peptides. Additionally, full-length toxins
are suitable for investigating the Hsc70-toxin interaction using a variety of other
commonly used methods to study protein-protein interactions such as dot blots,
protein thermal shift assays, and circular dichroism studies [103, 134, 135]. I’ve
created libraries of CTA1 and PTS1 mutants for future use in these studies.
69

Some AB toxins require cytosolic PIs for their Hsp90-driven translocation to the
cytosol [79, 87, 136] The Barth lab recently published that cyclophilins are also
required for PT activity [103]. Based on our studies, the block in PTS1 trafficking,
caused by CysA, is at the level of ER-to-cytosol translocation (Figure 13). CysA is
a generic cyclophilin inhibitor so it is not possible to say which cyclophilin is
responsible for PTS1 translocation. CypA is commonly associated with the
translocation of E-ADPRTs but I predict that ER-resident CypB is responsible for
PTS1 export to the cytosol. CypB is responsible for the export of ERAD substrates
with prolines in a cis conformation [128]. Prolines readily undergo isomerization
events, as discussed further in chapter 6, so it is likely that one or both of the RPP
proline within PTS1 are in a cis conformation that is recognized by CypB.
Remarkably, CTA1 does not require PIs for activity [42] which further demonstrates
how small toxin-to-toxin differences can influence co-chaperone interactions.

Initially we predicted that PTS1 followed the same Hsp90-driven, p97-independent
translocation pathway we previously established for CTA1 [41, 43]. We attempted
to determine the role of p97 in PTS1 translocation, but our results were
inconclusive. We used multiple p97 inhibitors, that all target the ATPase activity of
p97, and, while our results were reproducible for each drug treatment, our results
were not consistent between inhibitors. Future work should investigate if p97
interacts directly with PTS1. There are very few cell-based studies documenting
the specificity of p97 inhibitors. It is likely that these inhibitors are also affecting
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other ATPases, such as Hsp90, within the cell. It would be beneficial to study the
effects of various p97 inhibitors on Hsp90 binding and chaperone activities as well.

Our work has established that PTS1 follows an Hsp90-dependent translocation
mechanism that is similar to the one we’ve established for CTA1 [41-43]. We’ve
also highlighted that small differences in toxin-chaperone interactions for Hsc70,
and PIs, are observed, most likely as a result of minor toxin-to-toxin variations. It
is likely that other toxins follow a pathway similar that of PTS1 so it is crucial that
the roles of Hsc70 and PIs are established for more ER-ADPRTs. Our work has
used toxin A chains to provide a unique insight into chaperone biology, identifying
specific amino acid sequences that influence binding. Furthermore, we have
identified chaperone interactions that are required for PTS1 translocation to the
cytosol.
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CHAPTER 6: PROLINE ISOMERIZATION AS A DETERMINANT
FOR HSP90-TOXIN INTERACTIONS
Introduction
Typically, the trans conformation of peptide bonds is observed most of the time but
under certain conditions they are able to rotate to the cis state. In the case of
proline, the most common amino acid for cis/trans isomerization, the cis/trans
states are isoenergetic so neither state is preferred. The isomerization of proline is
considered to be the rate-limiting step in protein folding. In the case of p53, proline
isomerization dictates p53 function under stress conditions [137]. Additionally,
proline isomerization plays a role in the formation of -synuclein aggregates in
Parkinson’s disease as well as opening a neurotransmitter-gated ion channel [138,
139]. Protein-protein interactions can also be influenced by proline isomerization
[8, 140-142]. For example, PDI only recognizes RNase T1 with cis prolines. CypA,
a cytosolic PI, must place T1 in a conformation that can be recognized by PDI
[143]. We suspect that a similar interaction occurs between Hsp90 and the cis
conformation of prolines within the A chains of ADPRTs as evidenced below.

Hsp90
Hsp90 has been shown to demonstrate a high substrate specificity between its
wide range of clients however Hsp90 has not been shown to recognize any specific
sequence or motif [44, 92, 93, 144]. Co-chaperones are usually a key factor in
Hsp90 client recognition, which often begins with client recognition by Hsp40.
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Cytosolic chaperone Hsp70 is then recruited to the client, followed by the
Hsp70/Hsp90 organizing protein (HOP) and eventually Hsp90. Other chaperones,
such as PIs, can further regulate Hsp90-client interactions. After refolding, client
release from Hsp90 is mediated by ATP hydrolysis, which changes Hsp90 from a
“closed” to an “open” conformation. This general cycle of ATP hydrolysis coupled
with client binding and release is associated with the reactivation of the A chains
of bacterial AB toxins in the cytosol of intoxicated cells.

Toxin translocation from the endosomes to the cytosol
Once inside the cell, the acidic environment of the endosomes causes a
conformational change in the B subunit that creates a protein-conducting channel
within the endosomal membrane. The disordered A chain then passes through the
newly created pore to the cytosol where it is then free to modify its cytosolic target.
While some toxin A chains exploit a pH-driven ratchet mechanism for their delivery
to the cytosol [145], other toxins rely on host chaperones for their extraction from
the ER. Endosome-translocating toxins with ADP-ribosyl transferase activity rely
on Hsp90 for their translocation to the cytosol [75-79, 81]. It should be noted that
these toxins also require the activity of PIs for export to the cytosol [78, 79, 81,
136, 146, 147]. It is quite possible that both Hsp90 and PIs interact with a specific
feature of the toxin A chains, but so far none has been identified.
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Toxin translocation from the ER to the cytosol
ER-translocating toxins disassemble in the ER, followed by the unfolding of the
toxin A subunit [49]. A chain unfolding is caused by the thermal instability of some
toxin A chains or by interactions of the toxin A chain with anionic ER phospholipids
[51, 116, 148-150]. The disordered toxin A chain activates ERAD to export the
toxin A chain to the cytosol [53-55, 115, 151-155]. Typically, ERAD substrates are
ubiquitinated upon export, which targets them to the proteasome for degradation.
ER-translocating ADPRTs are able to escape degradation because they are
refolded by host chaperones as they exit the ER and they lack the lysine residues
required for ubiquitination within the cytosol [122, 124, 156, 157].

CT belongs to a subset of toxins that require Hsp90 for their activity. Hsp90 refolds
the toxin A chain as it emerges from the ER, ensuring a unidirectional translocation
event [41, 43]. The toxin maintains its folded state by a continued association with
Hsp90 so that it can modify its cytosolic target [43, 73]. We have demonstrated
Hsp90 recognizes an RPPDEI motif within CTA1 as it emerges on the cytosolic
face of the ER membrane (Chapter 2). Furthermore, we have observed that both
of the prolines with the RPPDEI motif are required for translocation of CTA1 to the
cytosol (Chapter 3). The RPPDEI motif is conserved within other ER-translocating
ADPRTs, suggesting that ER-translocating ADPRTs exploit a common Hsp90dependent pathway. Endosome-translocating ADPRTs that require Hsp90 also
require the action of PIs, but that is not the case for CT [42] suggesting that ER74

ADPRTs and E-ADPRTS may exploit similar but unique Hsp90-dependent
translocation mechanisms.
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Table 10 Hsp90 role in intoxication and translocation
Hsp90 role in
ADPRTs:
CT

RPPDEI

Intoxication
+

Translocation
+

LT

RPPDEI

?

?

PT

RPPEDV

?

+

ArtAB

RRPDVI

?

?

ETA

PGKPPR

+

?

TT

TPPDVI

?

?

CARD-T

RSPEEI

?

?

+

-

[80]

Other toxins:
ST1
N/A

Ref
[37,39]
Figure 12
[81]

ST2

N/A

-

-

[81]

RT

N/A

-

-

[81]

RPPDEI-like motifs are listed in the second column where applicable. A role for
Hsp90 in intoxication and/or translocation is indicated by a (+) or (-) for each toxin.
Typhoid toxin (TT) and community-acquired respiratory distress syndrome toxin
(CARD-T) do not contain an RPP sequence and it has yet to be determined if
Hsp90 is involved in their activities [158, 159].
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Atypical chaperone interactions drive translocation and cytosolic activity of CTA1
Hsp90 is able to recognize the RPPDEI motif within CTA1 without the need for cochaperones, making this is a highly unusual interaction. Remarkably, Hsp90
cannot bind to CTA1 in a folded conformation [41] even though the RPPDEI
binding motif is surface exposed (Figure 14). Refolded clients are typically
released from Hsp90 upon the hydrolysis of ATP, but CTA1 does not get released
from Hsp90 [41, 43, 93, 160]. We predict that proline isomerization in the RPPDEI
motif is the molecular mechanism behind this atypical Hsp90 interaction. The
unfolding event that occurs within the ER upon CTA1 dissociation causes CTA1 to
relax into a state that alters the conformation of one, or both, RPPDEI proline(s)
into a form that is recognized by Hsp90.
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Figure 14 An Hsp90 binding site within CTA1
A diagram of ordered CTA1 within the CT holotoxin (PDB 1XTC). The RPPDEI
prolines are highlighted in red while the remaining R,D,E, and I residues are
highlighted in yellow.
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Hypothesis: Proline isomerization plays a key role in toxin recognition by Hsp90
We predict that the order-disorder transitions of CTA1 affect proline isomerization
within its RPPDEI motif and that Hsp90 only recognizes prolines in the cisconformation. Holotoxin-associated CTA1 contains prolines in the trans
conformation within the RPPDEI motif (Dr. James Harper, unpublished
observation) which explains why Hsp90 does not recognize folded CTA1 [43].
When proteins unfold, they often undergo proline isomerization with Pro-Pro
peptide bonds favoring the cis form more than other Xaa-Pro peptide bonds, where
Xaa represents any amino acid [161-163]. Based on this information, we predict
that, upon unfolding, CTA1 relaxes into a state that allows the prolines of the
RPPDEI motif to isomerize to the cis state. As CTA1 emerges from the cytosolic
face of the ER membrane, Hsp90 interacts with the cis prolines within the RPPDEI
motif, beginning the extraction process. If CTA1 retains its cis prolines after
refolding, then Hsp90 would remain bound to the toxin, ensuring CTA1 is in an
active conformation for the modification of its target. This is consistent with
previous reports that Hsp90 remains bound to CTA1 with a 7 nM affinity [41, 42].
Our model is based upon studies involving CTA1, but the presence of similar motifs
in other toxin A chains (Chapter 4) suggests that our model could apply to ERADPRTs as a whole.

Proline isomerization could be the molecular basis for recognition of the RPP motif
within ER-ADPRTs by Hsp90. CT doesn’t require PIs [42], as commonly seen in
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E-ADPRTs that do not contain an RPP motif, [86, 103]. Therefore, we predict one
or more of the prolines in the RPP motif of disordered CTA1 is already in the proper
cis conformation, due to the unfolding event, for interaction with Hsp90. It is
currently accepted that the role of PIs in Hsp90-mediated protein folding is simply
to shorten the rate-limiting step of proline isomerization [87] during folding.
Perhaps PIs are also needed within the Hsp90 machinery complex [45, 57, 58,
164] to isomerize prolines within client proteins to an Hsp90-recognizable
conformation.

Discussion
The role of proline isomerization in protein structure and function is well
established, but to date it is not believed to influence Hsp90 client recognition [137,
138]. Co-chaperones are usually responsible for client specificity, as Hsp90 has
not been shown to recognize any specific amino acid sequence [44]. We have
shown that Hsp90 recognizes an RPPDEI motif within CTA1 that is required for
toxin activity. Furthermore, we have identified RPPDEI-like motifs within several
other ER-ADPRTs. We hypothesize that Hsp90 recognizes the prolines within the
RPPDEI motif of disordered CTA1 because the ER-localized unfolding event
relaxes the prolines into a cis conformation. A mutation of the arginine or either
proline residue is sufficient to block CTA1 export to the cytosol suggesting that all
three residues play a role in Hsp90 recognition. Endosome-translocating toxins
rely on cytosolic PIs for Hsp90 interaction because they lack the RPPDEI-like motif
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required for spontaneous trans-to-cis isomerization that may occur during the
unfolding event that precedes translocation. Prolyl isomerization within the A
chains of ADPRTs thus provides new insight into the roles that Hsp90 and PIs play
in translocation and intoxication.
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CHAPTER 7: GENERAL DISCUSSION
AB toxins have evolved to exploit host functions for their own productive
intoxication. AB toxins utilize their cell-binding B subunit to gain entry to the cell [9,
41]. Once inside the cell, toxins travel within endosomes. A subset of AB toxins
has evolved to respond to the acidic environment within endosomes. A
conformational change in the B subunit causes the release of the toxin A chain
from the rest of the toxin. The B subunit stays embedded within the endosomal
membrane, serving as a protein-conducting channel for the escape of the A
subunit. Toxin A chains rely on either a pH-driven ratchet mechanism, or the
actions of cytosolic Hsp90 [82] for their extraction from the endosomes [42, 86].
Another group of AB toxins traffic to the ER, where they exploit ERAD for their
productive intoxication. Once inside the ER, the A subunit dissociates from the rest
of the toxin and unfolds. This unfolding event causes the disordered toxin A chain
to be exported to the cytosol by ERAD. The toxin A chain is then refolded,
presumably by host factors, and goes on to modify its cytosolic target [42, 49, 55].
Our extensive work with CT, an ER-ADPRT, has shown that both Hsp90 and
Hsc70 are required for its activity [41-43]. Furthermore, we have shown that these
two chaperones are required at the level of CTA1 translocation from the ER, to the
cytosol.

Based on extensive studies involving E-ADPRTs, it was suggested that Hsp90
likely plays a role in translocation for all ADPRTs [87]. Furthermore, it is believed
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that Hsp90 likely recognizes a conserved feature of ADPRTs, although no Hsp90
binding motifs have ever been identified. We have identified two distinct amino acid
sequences within CTA1, RPPDEI and LDIAPA, that are specifically recognized by
Hsp90. Additionally, we have identified a YYIYVI sequence within CTA1 that is
specifically recognized by Hsc70. Both Hsp90 and Hsc70 are able to refold CTA1
and, as such, we predict that Hsp90 and Hsc70 couple toxin refolding with
translocation of CTA1 across the ER membrane. Based on the location of the
chaperone binding sites, we conclude that CTA1 must exit the ER in an N-to-Cterminal fashion. We predict that Hsp90 recognizes the RPPDEI motif, as it is
exposed, on the cytosolic face of the translocon pore. Hsp90 then initiates ATPmediated refolding of CTA1, ensuring a unidirectional movement, as a folded toxin
could no longer slide back into the ER through the translocon pore. As the toxin
exits the ER, the YYIYVI motif is exposed and then recognized by Hsc70. Hsp90
and Hsc70 then work together to extract CTA1 and ensure it is in an active
conformation to ADP-ribosylate its cytosolic target.

Hsp90 is thought to recognize a conserved feature within toxin A chains, so we
examined other ER-translocating toxin A chains for either of the Hsp90 binding
sites. We found that an RPPDEI-like motif, recognized by Hsp90, was present in
toxins with ADP-ribosyltransferase activity. We did not find either binding motif
within toxins that have a different catalytic activity. We then searched for Hsp90
binding motifs within the A chains of endosome toxins, ADPRTs as well as toxins
83

with other catalytic activities, and were unable to find any Hsp90 binding sites.
Based on these results, we conclude that ER-ADPRTs exploit an Hsp90-driven
translocation mechanism, different from that of E-ADPRTs, for their extraction to
the cytosol. Specifically, Hsp90 recognizes an N-terminal RPPDEI-like motif within
ER-ADPRT A chains, as they emerge from the ER. Hsp90-mediated refolding is
then coupled with toxin extraction from the ER. The refolded toxin can no longer
slide backwards through the translocon pore, ensuring a unidirectional export to
the cytosol [42, 43]. Hsp90 client recognition is believed to be dictated by cochaperones, yet our work has demonstrated a direct interaction between Hsp90
and toxin A chains, without the need for co-chaperones. We have demonstrated
that Hsp90 recognizes a conserved RPP motif within a subset of disordered toxin
A chains. As discussed in chapter 6, proline residues readily undergo cis/trans
isomerization, with Pro-Pro bonds favoring the cis conformation. We predict that
during the unfolding event within the ER, the prolines within the RPP motif of ERADPRTs relax to adopt a cis conformation. Furthermore, we predict that the cis
conformation of proline is specifically recognized by Hsp90. Our work has thus
used toxin biology to provide novel insight into chaperone biology. We have
identified an atypical Hsp90-toxin interaction that is dictated by prolyl
isomerization, providing insight into Hsp90 client-recognition. We often ignore the
isomerization state of prolines [8], but it is likely based on our studies, that prolyl
isomerization contributes to Hsp90 recognition of native client proteins as well. It
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should therefore be considered as a potential molecular determinant in future
Hsp90-client interaction studies.

In addition to determining the directionality of ER-to-cytosol transport, the locations
of the Hsp90 and Hsc70 chaperone binding sites dictate the order of chaperone
interactions with CTA1. According to our model, Hsp90 begins the extraction
process by binding to the N-terminal RPPDEI motif within CTA1. Hsp90-mediated
refolding drives toxin extraction until the Hsc70 binding site is exposed, then Hsc70
binds and assists in the refolding and extraction of CTA1 [42]. Our results indicate
that the second Hsp90 binding site within CTA1, LDIAPA, is required for
translocation as well, so it is likely that Hsp90 interacts with CTA1 a second time,
to finalize the refolding and extraction processes. Remarkably, only CTA1 and
LTA1 contain an LDIAPA-like motif suggesting they may employ a slightly different
Hsp90-mediated pathway than other ER-ADPRTs. It is likely that other ERADPRTs, lacking the LDIAPA motif, do not interact with Hsp90 a second time,
although this has yet to be tested. We predict that proline isomerization likely plays
a role in Hsp90 recognition of one, or both of the RPPDEI proline residues. So, it
is possible that the proline residue within the LDIAPA motif is responsible for the
additional interaction with Hsp90 observed with CTA1. In future studies, a valine
substitution within our ssCTA1 construct could be used to determine if the proline
residue is required for Hsp90-mediated translocation. Additional studies should be
conducted, to determine if the LNIAPA sequence, found within LTA1 interacts with
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Hsp90 directly. It is possible, based on evidence from our Hsc70 studies, that the
polar N for a charged D substitution could be sufficient to abolish Hsp90
recognition within the LDIAPA-like binding site of LTA1.

PT, like CT, is an ER-ADPRT that contains an RPPEDV Hsp90 binding motif,
although all of the host factors required for PTS1 translocation to the cytosol have
yet to be identified. We predicted that PTS1 translocation is an Hsp90-driven
process, based on its RPPEDV Hsp90 binding motif, which we confirmed with our
targeted translocation assay. A recent study suggests that all ADPRTs likely
require Hsc70 and PIs, in addition to Hsp90, for their activity [103]. Hsc70 is
required, in addition to Hsp90, for CTA1 translocation to the cytosol [42]. Our work
has determined that Hsc70 recognizes a YYIYVI motif within CTA1. PTS1 contains
a YYIYVI-like motif, GYIYEV, and also requires Hsp90 for translocation, so we
predicted Hsc70 plays a role in PTS1 translocation. Remarkably, Hsc70 does not
interact with PTS1 suggesting PTS1 employs an Hsc70-dependent mechanism for
translocation to the cytosol. This appears to be only one of several small toxin-totoxin differences that influence chaperone interactions. Based on our results, it
appears that Hsc70 is able to discriminate between the two toxin A chains based
on a single amino acid difference, an E for a V substitution at CTA187. This is likely
because Hsc70 is believed to recognize stretches of 5-7 exposed hydrophobic
residues within client proteins [68, 69]. Swapping a charged E for a hydrophilic V
likely disrupts the hydrophilic stretch recognized by Hsc70. In contrast, Hsc70
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interaction was not influenced when we replaced an amphipathic Y residue with a
hydrophobic G residue, likely because the hydrophobic stretch was maintained
with this mutation. The V-for-I mutation in CTA1 at position 88 was not tested, and
could influence Hsc70 binding, so it should still be evaluated. Full-length CTA1
should be used, containing the mutation of interest, to overcome the SPR-coupling
issues experienced with the peptide. I predict that a V for I substitution will have
no effect on Hsc70 recognition, as both are hydrophobic in nature, and therefore,
the substitution should not disrupt the hydrophobic stretch required for an
interaction with Hsc70. Other toxin A chains, as well as native Hsc70 clients,
should be examined for the presence of a YYIYVI-like motif. Based on our studies
with toxin A chains we predict that native Hsc70 client proteins could utilize a
YYIYVI-like motif for their interactions with Hsc70 as well.

Another key difference in PTS1 translocation, is the requirement of PIs for
translocation (Chapter 5) [103]. CTA1 does not require the activity of PIs, even
though the two toxins share the same Hsp90-driven translocation pathway [42].
Our work indicates that while all ER-ADPRTs likely utilize Hsp90 for their
translocation, they each require different cohorts of co-chaperones. Peptide-based
screens, similar to those used to screen for Hsp90 and Hsc70 binding sites, could
be utilized to identify additional chaperone binding motifs within each toxin A chain.
This would determine which chaperones interact with which toxins. The order of
the binding sites would also dictate the order of chaperone interactions for each
87

toxin. Our work thus provides the framework for understanding the events of toxin
translocation in general. Additionally, we have demonstrated that toxin A chains
can be utilized to understand the molecular details of client recognition by
chaperones.
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